Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01828619|
Recruitment Status : Unknown
Verified April 2013 by FENGRONG WANG, Peking University People's Hospital.
Recruitment status was: Enrolling by invitation
First Posted : April 10, 2013
Last Update Posted : April 10, 2013
|Condition or disease||Intervention/treatment|
|Leukemia Myelodysplastic Syndrome||Procedure: modified BuFlu conditioning|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases|
|Study Start Date :||February 2013|
|Estimated Primary Completion Date :||December 2015|
modified BuFlu, HSCT, elder/intolerable
The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
Procedure: modified BuFlu conditioning
The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
- stem cell engraftment [ Time Frame: 30day post transplantation ]
- toxicity and treatment related mortality [ Time Frame: 100day and 1 year post transplantation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828619
|Peking University People's Hospital|
|Beijing, China, 100044|
|Principal Investigator:||XiaoJun Huang, MD||Peking University People's Hospital, Department of Hematology|